Core Viewpoint - The legal opinion from Zhonglun Law Firm addresses the conditions for the third vesting period of the restricted stock incentive plan of Kanglong Chemical (Beijing) New Drug Technology Co., Ltd., indicating that the conditions have been met but the stocks will not be listed for trading at this time [1][12]. Summary by Sections Legal Opinion Overview - The legal opinion is based on the review of the 2022 A-share restricted stock incentive plan and related documents, confirming compliance with relevant laws and regulations [4][7]. Approval and Authorization - The adjustments, vesting, and cancellation of certain restricted stocks have been approved by the company's board and independent directors, ensuring compliance with the management regulations [6][8]. Vesting Conditions - The third vesting period for the restricted stocks is defined as starting from the first trading day after 36 months from the grant date, which was July 28, 2022, and will last until the last trading day within 48 months [8][11]. - The conditions for vesting have been met, including no adverse audit opinions and the fulfillment of performance targets [9][10]. Performance Metrics - The company’s revenue for 2024 is projected to be approximately 12.28 billion, representing a growth of at least 60% compared to 2021's revenue of about 7.44 billion [9][10]. Cancellation of Restricted Stocks - A total of 44,104 shares of restricted stock granted to 10 individuals who left the company have been declared void, in accordance with the incentive plan [11][12]. Conclusion - The legal opinion concludes that all necessary approvals have been obtained, the third vesting period conditions have been satisfied, and the actions taken are in compliance with applicable laws and regulations [12].

证券代码：002796 证券简称：世嘉科技 公告编号：2025-040 苏州市世嘉科技股份有限公司 第五届监事会第四次会议决议公告 本公司及监事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏。 一、监事会会议召开情况 苏州市世嘉科技股份有限公司（以下简称"公司"或者"世嘉科技"）第五 届监事会第四次会议于 2025 年 8 月 11 日以专人送达、电子邮件、电话通知等方 式通知了全体监事，会议于 2025 年 8 月 21 日在公司会议室以现场结合通讯的方 式召开。会议由公司监事会主席汤新华先生召集和主持，应到监事 3 人，实到监 事 3 人。本次会议的召集和召开程序、出席人数、审议和表决程序均符合《中华 人民共和国公司法》（以下简称"《公司法》"）及《苏州市世嘉科技股份有限 公司章程》（以下简称"《公司章程》"）等有关规定。 二、监事会会议审议情况 经审核，监事会认为：公司 2024 年限制性股票激励计划的预留授予日和激 励对象均符合《上市公司股权激励管理办法》《苏州市世嘉科技股份有限公司 均未发生不得授予限制性股票的情况，本次激励计划的授予条件已经成就。因此， 监事会同意以 ...

上海市锦天城（深圳）律师事务所 关于 开普云信息科技股份有限公司 调整授予价格 之 法律意见书 地址：深圳市福田中心区福华三路卓越世纪中心 1 号楼 21-23 层 电话：0755-82816698 传真：0755-82816898 上海市锦天城（深圳）律师事务所 关于 开普云信息科技股份有限公司 调整授予价格 之 法律意见书 致：开普云信息科技股份有限公司 上海市锦天城（深圳）律师事务所接受开普云信息科技股份有限公司（以下简 称"公司""开普云"）的委托，就开普云信息科技股份有限公司 2022 年限制性 股票激励计划（以下简称"本次激励计划"）涉及的有关事项出具本法律意见书。 为出具本法律意见书，本所特作如下声明： （一）在本法律意见书中，本所在《上市公司股权激励管理办法》规定的范围 内对本法律意见书出具日以前已经发生或存在的且与本次激励计划有关的重要法 律事项发表法律意见，并不对其他事项以及财务、审计、股票投资价值、本次激励 计划的业绩考核标准等非法律事项发表意见； （二）本法律意见书涉及财务、审计等内容的，本所严格按照有关方出具的专 业文件（包括但不限于审计报告、内部控制审计报告）进行引用，但引用行为并 ...

证券代码：603040 证券简称：新坐标 公告编号：2025-038 杭州新坐标科技股份有限公司 第五届监事会第十一次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 杭州新坐标科技股份有限公司监事会 杭州新坐标科技股份有限公司（以下简称"公司"或"新坐标"）于 2025 年 8 月 13 日在公司会议室以现场结合通讯表决方式召开第五届监事会第十一次 会议。会议通知已于 2025 年 8 月 8 日以专人送达及电子邮件方式发出。本次会 议应到监事 3 名，实到监事 3 名。会议由监事会主席季红英女士主持，会议的召 集与召开符合《公司法》及《公司章程》的有关规定。 二、监事会会议审议情况 与会监事审议通过了如下议案： 监事会审议并发表如下审核意见：激励对象不存在被交易所公开谴责或宣布 为不适当人选的情况，也不存在因重大违规行为被中国证监会予以行政处罚的情 况，激励对象符合《上市公司股权激励管理办法》、《公司 2024 年限制性股票 激励计划（草案）》以及《公司 2024 年限制性股票激励计划实施考核管理办法》 等相关 ...

优彩环保资源科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏. 优彩环保资源科技股份有限公司（以下简称"公司"）第四届监事会第六 次会议通知于2025年8月6日通过书面通知的方式送达。会议于2025年8月11 日以现场会议的方式在公司会议室召开，由监事会主席孔诚先生召集并主持， 本次会议应出席监事3名，实际出席监事3名，占公司全体监事人数的100%。 本次会议的召集、召开程序和议事内容均符合《中华人民共和国公司法》、 《优彩环保资源科技股份有限公司章程》等有关规定。 证券代码：002998 证券简称：优彩资源 公告编号：2025-036 债券代码：127078 债券简称：优彩转债 的议案》。 表决结果：3 票同意，0 名反对，0 名弃权。 监事会认为：（1）列入公司本次股权激励计划激励对象名单的人员具备《公 司法》等法律、法规和规范性文件及《公司章程》规定的任职资格。 一、监事会会议审议情况 经与会监事认真审议、表决，会议形成如下决议： 的议案》。 表决结果：3 票同意，0 名反对，0 名弃权。 监事会认为：本次激励计划内容符合《公司法》、《证券 ...

Core Viewpoint - The company has publicly disclosed the list of candidates for the 2024 restricted stock incentive plan and confirmed that all candidates meet the necessary legal and regulatory requirements [2][4]. Group 1: Public Disclosure and Verification - The company conducted a public announcement regarding the candidates for the 2024 restricted stock incentive plan, allowing employees to provide feedback during a 10-day public comment period [3]. - No objections were raised by employees during the public comment period regarding the proposed candidates for the incentive plan [3]. - The verification process included checking the candidates' identities, employment contracts, and their roles within the company and its subsidiaries [3]. Group 2: Committee Review and Compliance - The Board's Compensation and Assessment Committee reviewed the candidates' qualifications against relevant laws and regulations, confirming that all listed candidates are eligible for the incentive plan [4]. - The committee ensured that none of the candidates fell under disqualifying conditions as outlined in the applicable laws and regulations [4].

Core Viewpoint - Jiangsu Chengxing Phosphate Chemical Co., Ltd. has announced the public disclosure and verification opinions regarding the list of incentive objects for its 2025 restricted stock incentive plan, ensuring compliance with relevant regulations and confirming the legitimacy of the proposed recipients [1][2][3]. Group 1: Public Disclosure of Incentive Objects - The company held a board meeting on July 29, 2025, to approve the 2025 restricted stock incentive plan and publicly disclosed the draft and summary of the plan on the Shanghai Stock Exchange website [1]. - From July 30 to August 8, 2025, the company conducted a 10-day internal public disclosure of the names and positions of the proposed incentive objects, allowing employees to provide feedback [2]. - No objections were raised by any organization or individual during the public disclosure period [2]. Group 2: Verification by the Compensation and Assessment Committee - The Compensation and Assessment Committee verified the list of proposed incentive objects, including their identification, employment contracts, positions, and appointment documents [2][3]. - The committee confirmed that the proposed incentive objects meet the qualifications stipulated in the management regulations and company articles [3]. Group 3: Committee's Verification Opinions - The committee stated that the basic information of the proposed incentive objects is accurate and does not contain any falsehoods or significant omissions [3]. - All proposed incentive objects are current directors, senior management, core management, key employees, and high-potential talents at the time of the announcement [3]. - The proposed incentive objects do not include independent directors, supervisors, or shareholders holding more than 5% of the company's shares [3].

证券代码：688083 证券简称：中望软件 公告编号：2025-045 广州中望龙腾软件股份有限公司 关于调整 2024 年限制性股票激励计划 授予价格及授予数量的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 广州中望龙腾软件股份有限公司（以下简称"公司"）于 2025 年 8 月 7 日召 开第六届董事会第十六次会议，审议通过了《关于调整 2024 年限制性股票激励 计划授予价格及授予数量的议案》。根据公司《2024 年限制性股票激励计划（草 案）》（以下简称"本激励计划"或"《激励计划（草案）》"）的有关规定及公司 量进行了调整。现将有关事项说明如下： 一、本次限制性股票激励计划已履行的决策程序和信息披露情况 了《关于 <广州中望龙腾软件股份有限公司 ensp="ensp" 年限制性股票激励计划="年限制性股票激励计 划" 草案="草案"> 及其摘要的议案》《关于 <广州中望龙腾软件股份有限公司 ensp="ensp" 年限制性股票激="年限制性股 票激"> 励计划实施考核管理办法>的议案》以及《关于提请股东大会授 ...

Core Viewpoint - The legal opinion letter from Grandall Law Firm (Shanghai) confirms that Hubei Jichuan Pharmaceutical Co., Ltd. has obtained the necessary approvals and authorizations for the cancellation of certain stock options and the repurchase of restricted stocks, in accordance with relevant laws and regulations [2][12]. Group 1: Approval and Authorization - The company held multiple board meetings and a shareholders' meeting in 2022 and 2023 to approve the incentive plan and related matters, with independent directors providing their consent [5][6][7]. - The legal opinion states that the company has complied with the necessary legal requirements and has conducted thorough verification of the facts and legal issues related to the incentive plan [3][4]. Group 2: Details of Cancellation and Repurchase - The company plans to cancel a total of 264,000 stock options and repurchase 219,000 restricted stocks due to the departure of 9 incentive recipients, and an additional 318,500 stock options and restricted stocks due to the demotion of 22 recipients [9][10]. - The repurchase price for the restricted stocks will be based on the grant price plus interest from the People's Bank of China, with specific prices set for different batches of stocks [10]. Group 3: Funding and Disclosure - The funding for the repurchase will come from the company's own funds, and a dedicated securities account has been established for this purpose [10]. - The company has fulfilled its obligation to disclose information regarding the repurchase and cancellation, with announcements made in accordance with regulatory requirements [11][12].

公司于 2025 年 4 月 25 日召开第十届董事会第十四次会议，审议通过了《关 于注销部分股票期权并回购注销部分限制性股票的议案》：鉴于 14 名激励对象 离职、1 名激励对象退休，根据本激励计划的相关规定，公司拟注销上述激励对 象已获授但尚未行权的股票期权 65.6 万份(其中首次授予股票期权数量 35.8 万 份，预留授予（第一批）股票期权数量 25.3 万份，预留授予（第二批）股票期 权数量 4.5 万份)，拟回购注销上述激励对象已获授但尚未解除限售的限制性股 票 50.6 万股(首次授予限制性股票数量 20.8 万股，预留授予(第一批)限制性股 票数量 25.3 万股，预留授予(第二批)限制性股票数量 4.5 万股)。 证券代码：600566 证券简称：济川药业 公告编号： 2025-061 湖北济川药业股份有限公司 关于 2022 年限制性股票与股票期权激励计划 部分限制性股票回购注销实施的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ?回购注销原因：湖北济川药业股份有限公司（以下简称"公 ...